Degraders upgraded: the rise of PROTACs in hematological malignancies

2.

Kiriiri

GK

,

Njogu

PM

,

Mwangi

AN

.

Exploring different approaches to improve the success of drug discovery and development projects: a review

.

Futur J Pharm Sci

.

2020

;

6

(

1

):

27

.

3.

Hinkson

IV

,

Madej

B

,

Stahlberg

EA

.

Accelerating therapeutics for opportunities in medicine: a paradigm shift in drug discovery

.

Front Pharmacol

.

2020

;

11

:

770

.

4.

Dowden

H

,

Munro

J

.

Trends in clinical success rates and therapeutic focus

.

Nat Rev Drug Discov

.

2019

;

18

(

7

):

495

-

496

.

5.

Neklesa

TK

,

Winkler

JD

,

Crews

CM

.

Targeted protein degradation by PROTACs

.

Pharmacol Ther

.

2017

;

174

:

138

-

144

.

6.

Olsen

SK

,

Lima

CD

.

Structure of a ubiquitin E1-E2 complex: insights to E1-E2 thioester transfer

.

Mol Cell

.

2013

;

49

(

5

):

884

-

896

.

7.

Lee

I

,

Schindelin

H

.

Structural insights into E1-catalyzed ubiquitin activation and transfer to conjugating enzymes

.

Cell

.

2008

;

134

(

2

):

268

-

278

.

8.

DeMartino

GN

,

Slaughter

CA

.

The proteasome, a novel protease regulated by multiple mechanisms

.

J Biol Chem

.

1999

;

274

(

32

):

22123

-

22126

.

9.

Verma

R

,

Oania

R

,

Graumann

J

,

Deshaies

RJ

.

Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system

.

Cell

.

2004

;

118

(

1

):

99

-

110

.

10.

Yao

T

,

Cohen

RE

.

A cryptic protease couples deubiquitination and degradation by the proteasome

.

Nature

.

2002

;

419

(

6905

):

403

-

407

.

11.

Deshaies

RJ

,

Joazeiro

CAP

.

RING domain E3 ubiquitin ligases

.

Annu Rev Biochem

.

2009

;

78

(

1

):

399

-

434

.

12.

Abbas

R

,

Larisch

S

.

Killing by degradation: regulation of apoptosis by the ubiquitin-proteasome-system

.

Cells

.

2021

;

10

(

12

):

3465

.

13.

Kleiger

G

,

Mayor

T

.

Perilous journey: a tour of the ubiquitin–proteasome system

.

Trends Cell Biol

.

2014

;

24

(

6

):

352

-

359

.

14.

Sakamoto

KM

,

Kim

KB

,

Kumagai

A

,

Mercurio

F

,

Crews

CM

,

Deshaies

RJ

.

Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

.

Proc National Acad Sci

.

2001

;

98

(

15

):

8554

-

8559

.

15.

Sakamoto

KM

,

Kim

KB

,

Verma

R

, et al.

Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation

.

Mol Cell Proteomics

.

2003

;

2

(

12

):

1350

-

1358

.

16.

Schneekloth

AR

,

Pucheault

M

,

Tae

HS

,

Crews

CM

.

Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics

.

Bioorg Med Chem Lett

.

2008

;

18

(

22

):

5904

-

5908

.

17.

Ito

T

,

Ando

H

,

Suzuki

T

, et al.

Identification of a primary target of thalidomide teratogenicity

.

Science

.

2010

;

327

(

5971

):

1345

-

1350

.

18.

Gadd

MS

,

Testa

A

,

Lucas

X

, et al.

Structural basis of PROTAC cooperative recognition for selective protein degradation

.

Nat Chem Biol

.

2017

;

13

(

5

):

514

-

521

.

19.

Luo

X

,

Archibeque

I

,

Dellamaggiore

K

, et al.

Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases

.

Iscience

.

2022

;

25

(

3

):

103985

.

20.

Khan

S

,

Zhang

X

,

Lv

D

, et al.

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

.

Nat Med

.

2019

;

25

(

12

):

1938

-

1947

.

21.

Ahmad

G

,

Mohapatra

BC

,

Schulte

NA

, et al.

Cbl-family ubiquitin ligases and their recruitment of CIN85 are largely dispensable for epidermal growth factor receptor endocytosis

.

Int J Biochem Cell Biol

.

2014

;

57

:

123

-

134

.

22.

Wade

M

,

Wahl

GM

.

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

.

Mol Cancer Res

.

2009

;

7

(

1

):

1

-

11

.

23.

Békés

M

,

Langley

DR

,

Crews

CM

.

PROTAC targeted protein degraders: the past is prologue

.

Nat Rev Drug Discov

.

2022

;

21

(

3

):

181

-

200

.

24.

Belcher

BP

,

Ward

CC

,

Nomura

DK

.

Ligandability of E3 ligases for targeted protein degradation applications

.

Biochemistry-us

.

2023

;

62

(

3

):

588

-

600

.

25.

Boike

L

,

Henning

NJ

,

Nomura

DK

.

Advances in covalent drug discovery

.

Nat Rev Drug Discov

.

2022

;

21

(

12

):

881

-

898

.

26.

Zhang

QC

,

Petrey

D

,

Deng

L

, et al.

Structure-based prediction of protein–protein interactions on a genome-wide scale

.

Nature

.

2012

;

490

(

7421

):

556

-

560

.

27.

Bricelj

A

,

Steinebach

C

,

Kuchta

R

,

Gütschow

M

,

Sosič

I

.

E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points

.

Front Chem

.

2021

;

9

:

707317

.

28.

Nowak

RP

,

DeAngelo

SL

,

Buckley

D

, et al.

Plasticity in binding confers selectivity in ligand-induced protein degradation

.

Nat Chem Biol

.

2018

;

14

(

7

):

706

-

714

.

29.

Bemis

TA

,

La Clair

JJ

,

Burkart

MD

.

Unraveling the role of linker design in proteolysis targeting chimeras

.

J Med Chem

.

2021

;

64

(

12

):

8042

-

8052

.

30.

Smith

BE

,

Wang

SL

,

Jaime-Figueroa

S

, et al.

Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase

.

Nat Commun

.

2019

;

10

(

1

):

131

.

31.

Bricelj

A

,

Dora Ng

YL

,

Ferber

D

, et al.

Influence of linker attachment points on the stability and neosubstrate degradation of cereblon ligands

.

ACS Med Chem Lett

.

2021

;

12

(

11

):

1733

-

1738

.

32.

Schiemer

J

,

Horst

R

,

Meng

Y

, et al.

Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes

.

Nat Chem Biol

.

2021

;

17

(

2

):

152

-

160

.

33.

Atilaw

Y

,

Poongavanam

V

,

Svensson Nilsson

C

, et al.

Solution conformations shed light on PROTAC cell permeability

.

ACS Med Chem Lett

.

2021

;

12

(

1

):

107

-

114

.

34.

Goodnow

RA

,

Dumelin

CE

,

Keefe

AD

.

DNA-encoded chemistry: enabling the deeper sampling of chemical space

.

Nat Rev Drug Discov

.

2017

;

16

(

2

):

131

-

147

.

35.

Disch

JS

,

Duffy

JM

,

Lee

ECY

, et al.

Bispecific estrogen receptor α degraders incorporating novel binders identified using DNA-encoded chemical library screening

.

J Med Chem

.

2021

;

64

(

8

):

5049

-

5066

.

36.

Ishida

T

,

Ciulli

A

.

E3 ligase ligands for PROTACs: how they were found and how to discover new ones

.

Slas Discov

.

2021

;

26

(

4

):

484

-

502

.

37.

Chen

Q

,

Liu

C

,

Wang

W

, et al.

Optimization of PROTAC ternary complex using DNA encoded library approach

.

ACS Chem Biol

.

2023

;

18

(

1

):

25

-

33

.

38.

Sunkari

YK

,

Siripuram

VK

,

Nguyen

T-L

,

Flajolet

M

.

High-power screening (HPS) empowered by DNA-encoded libraries

.

Trends Pharmacol Sci

.

2022

;

43

(

1

):

4

-

15

.

39.

Adjei

AA

.

What is the right dose? The elusive optimal biologic dose in phase I clinical trials

.

J Clin Oncol

.

2006

;

24

(

25

):

4054

-

4055

.

40.

Han

X

,

Zhao

L

,

Xiang

W

, et al.

Discovery of highly potent and efficient PROTAC degraders of androgen receptor (AR) by employing weak binding affinity VHL E3 ligase ligands

.

J Med Chem

.

2019

;

62

(

24

):

11218

-

11231

.

41.

Bondeson

DP

,

Smith

BE

,

Burslem

GM

, et al.

Lessons in PROTAC design from selective degradation with a promiscuous warhead

.

Cell Chem Biol

.

2018

;

25

(

1

):

78

-

87.e5

.

42.

Gechijian

LN

,

Buckley

DL

,

Lawlor

MA

, et al.

Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands

.

Nat Chem Biol

.

2018

;

14

(

4

):

405

-

412

.

43.

Huang

H-T

,

Dobrovolsky

D

,

Paulk

J

, et al.

A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader

.

Cell Chem Biol

.

2018

;

25

(

1

):

88

-

99.e6

.

44.

Zorba

A

,

Nguyen

C

,

Xu

Y

, et al.

Delineating the role of cooperativity in the design of potent PROTACs for BTK

.

Proc Natl Acad Sci U S A

.

2018

;

115

(

31

):

E7285

-

E7292

.

45.

Buckley

DL

,

Gustafson

JL

,

Van Molle

I

, et al.

Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α

.

Angew Chem Int Ed

.

2012

;

51

(

46

):

11463

-

11467

.

46.

Galdeano

C

,

Gadd

MS

,

Soares

P

, et al.

Structure-guided design and optimization of small molecules targeting the protein–protein interaction between the von Hippel–Lindau (VHL) E3 ubiquitin ligase and the Hypoxia Inducible Factor (HIF) alpha subunit with in vitro nanomolar affinities

.

J Med Chem

.

2014

;

57

(

20

):

8657

-

8663

.

47.

Zengerle

M

,

Chan

K-H

,

Ciulli

A

.

Selective small molecule induced degradation of the BET bromodomain protein BRD4

.

ACS Chem Biol

.

2015

;

10

(

8

):

1770

-

1777

.

48.

Tovell

H

,

Testa

A

,

Zhou

H

, et al.

Design and characterization of SGK3-PROTAC1, an isoform specific SGK3 kinase PROTAC degrader

.

ACS Chem Biol

.

2019

;

14

(

9

):

2024

-

2034

.

49.

Douglass

EF

,

Miller

CJ

,

Sparer

G

,

Shapiro

H

,

Spiegel

DA

.

A comprehensive mathematical model for three-body binding equilibria

.

J Am Chem Soc

.

2013

;

135

(

16

):

6092

-

6099

.

50.

Chamberlain

PP

,

Hamann

LG

.

Development of targeted protein degradation therapeutics

.

Nat Chem Biol

.

2019

;

15

(

10

):

937

-

944

.

51.

Buckley

DL

,

Raina

K

,

Darricarrere

N

, et al.

HaloPROTACS: use of small molecule PROTACs to induce degradation of HaloTag fusion proteins

.

ACS Chem Biol

.

2015

;

10

(

8

):

1831

-

1837

.

52.

Riching

KM

,

Caine

EA

,

Urh

M

,

Daniels

DL

.

The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation

.

Chem Soc Rev

.

2022

;

51

(

14

):

6210

-

6221

.

53.

Pettersson

M

,

Crews

CM

.

PROteolysis TArgeting Chimeras (PROTACs) — past, present and future

.

Drug Discov Today Technol

.

2019

;

31

:

15

-

27

.

54.

Poongavanam

V

,

Kihlberg

J

.

PROTAC cell permeability and oral bioavailability: a journey into uncharted territory

.

Future Med Chem

.

2022

;

14

(

3

):

123

-

126

.

55.

Lipinski

CA

,

Lombardo

F

,

Dominy

BW

,

Feeney

PJ

.

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

.

Adv Drug Deliv Rev

.

1997

;

23

(

1–3

):

3

-

25

.

56.

Cecchini

C

,

Pannilunghi

S

,

Tardy

S

,

Scapozza

L

.

From conception to development: investigating PROTACs features for improved cell permeability and successful protein degradation

.

Front Chem

.

2021

;

9

:

672267

.

57.

Lai

AC

,

Toure

M

,

Hellerschmied

D

, et al.

Modular PROTAC design for the degradation of oncogenic BCR-ABL

.

Angew Chem Int Ed

.

2016

;

55

(

2

):

807

-

810

.

58.

Jiang

B

,

Wang

ES

,

Donovan

KA

, et al.

Development of dual and selective degraders of cyclin-dependent kinases 4 and 6

.

Angew Chem Int Ed

.

2019

;

58

(

19

):

6321

-

6326

.

59.

Yamanaka

S

,

Furihata

H

,

Yanagihara

Y

, et al.

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

.

Nat Commun

.

2023

;

14

(

1

):

4683

.

60.

Ignatov

M

,

Jindal

A

,

Kotelnikov

S

, et al.

High accuracy prediction of PROTAC complex structures

.

J Am Chem Soc

.

2023

;

145

(

13

):

7123

-

7135

.

61.

Nowak

RP

,

Jones

LH

.

Target validation using PROTACs: applying the four pillars framework

.

SLAS Discov

.

2021

;

26

(

4

):

474

-

483

.

62.

Li

Z

,

Van Calcar

S

,

Qu

C

,

Cavenee

WK

,

Zhang

MQ

,

Ren

B

.

A global transcriptional regulatory role for c-Myc in Burkitt’s lymphoma cells

.

Proc Natl Acad Sci U S A

.

2003

;

100

(

14

):

8164

-

8169

.

63.

Fernandez

PC

,

Frank

SR

,

Wang

L

, et al.

Genomic targets of the human c-Myc protein

.

Genes Dev

.

2003

;

17

(

9

):

1115

-

1129

.

64.

Schick

M

,

Habringer

S

,

Nilsson

JA

,

Keller

U

.

Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers

.

Br J Haematol

.

2017

;

179

(

5

):

724

-

738

.

65.

Felsher

DW

.

MYC inactivation elicits oncogene addiction through both tumor cell–intrinsic and host-dependent mechanisms

.

Genes Cancer

.

2010

;

1

(

6

):

597

-

604

.

66.

Jain

M

,

Arvanitis

C

,

Chu

K

, et al.

Sustained loss of a neoplastic phenotype by brief inactivation of MYC

.

Science

.

2002

;

297

(

5578

):

102

-

104

.

67.

Fukazawa

T

,

Maeda

Y

,

Matsuoka

J

, et al.

Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc

.

Anticancer Res

.

2010

;

30

(

10

):

4193

-

4200

.

68.

Llombart

V

,

Mansour

MR

.

Therapeutic targeting of “undruggable” MYC

.

EBioMedicine

.

2022

;

75

:

103756

.

69.

Nishida

Y

,

Ayoub

E

,

Scruggs

D

, et al.

Stem-cell enriched cellular hierarchy of TP53 mutant acute myeloid leukemia is vulnerable to targeted protein degradation of c-MYC [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

583

.

70.

Munir

F

,

Khazaei

S

,

Calkins

PH

, et al.

Targeted protein degradation for c-MYC overcomes therapy resistance in T-cell acute lymphoblastic leukemias [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

1447

.

71.

Dawson

MA

,

Prinjha

RK

,

Dittmann

A

, et al.

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

.

Nature

.

2011

;

478

(

7370

):

529

-

533

.

72.

Lu

J

,

Qian

Y

,

Altieri

M

, et al.

Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4

.

Chem Biol

.

2015

;

22

(

6

):

755

-

763

.

73.

Ma

L

,

Wang

J

,

Zhang

Y

, et al.

BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes

.

Cancer Biol Ther

.

2022

;

23

(

1

):

1

-

15

.

74.

Zhang

K

,

Gao

L

,

Wang

J

, et al.

A novel BRD family PROTAC inhibitor dBET1 exerts great anti-cancer effects by targeting c-MYC in acute myeloid leukemia cells

.

Pathol Oncol Res

.

2022

;

28

:

1610447

.

75.

Qin

C

,

Hu

Y

,

Zhou

B

, et al.

Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression

.

J Med Chem

.

2018

;

61

(

15

):

6685

-

6704

.

76.

Piya

S

,

Mu

H

,

Bhattacharya

S

, et al.

BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment

.

J Clin Invest

.

2019

;

129

(

5

):

1878

-

1894

.

77.

Furukawa

K

,

Shimada

K

,

Esaki

M

, et al.

Development and efficacy of a novel bromodomain and extraterminal domain degrader K-256 in MYC/BCL2-related lymphoma [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

5008

.

78.

Johnson

DE

,

O’Keefe

RA

,

Grandis

JR

.

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

.

Nat Rev Clin Oncol

.

2018

;

15

(

4

):

234

-

248

.

79.

Frank

DA

.

STAT3 as a central mediator of neoplastic cellular transformation

.

Cancer Lett

.

2007

;

251

(

2

):

199

-

210

.

80.

Yu

H

,

Kortylewski

M

,

Pardoll

D

.

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment

.

Nat Rev Immunol

.

2007

;

7

(

1

):

41

-

51

.

81.

Lee

H-J

,

Zhuang

G

,

Cao

Y

,

Du

P

,

Kim

HJ

,

Settleman

J

.

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells

.

Cancer Cell

.

2014

;

26

(

2

):

207

-

221

.

82.

Levy

DE

,

Darnell

JE

.

STATs: transcriptional control and biological impact

.

Nat Rev Mol Cell Biol

.

2002

;

3

(

9

):

651

-

662

.

83.

Beebe

JD

,

Liu

J-Y

,

Zhang

J-T

.

Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?

.

Pharmacol Ther

.

2018

;

191

:

74

-

91

.

84.

Yang

J

,

Stark

GR

.

Roles of unphosphorylated STATs in signaling

.

Cell Res

.

2008

;

18

(

4

):

443

-

451

.

85.

Bai

L

,

Zhou

H

,

Xu

R

, et al.

A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo

.

Cancer Cell

.

2019

;

36

(

5

):

498

-

511.e17

.

86.

Zhou

H

,

Bai

L

,

Xu

R

, et al.

SD-91 as a potent and selective STAT3 degrader capable of achieving complete and long-lasting tumor regression

.

ACS Med Chem Lett

.

2021

;

12

(

6

):

996

-

1004

.

87.

Liu

PC

,

Dixit

V

,

Mayo

M

, et al.

A first-in-class STAT3 degrader KT-333 in development for treatment of hematologic cancers [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

1865

.

88.

Danilov

A

,

Tees

MT

,

Patel

K

, et al.

A first-in-human phase 1 trial of NX-2127, a first-in-class Bruton’s tyrosine kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed/refractory B cell malignancies [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

4463

.

89.

Searle

E

,

Forconi

F

,

Linton

K

, et al.

Initial findings from a first-in-human phase 1a/b trial of NX-5948, a selective Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

4473

.

90.

Seymour

JF

,

Cheah

CY

,

Parrondo

R

, et al.

First results from a phase 1, first-in-human study of the Bruton’s tyrosine kinase (BTK) degrader Bgb-16673 in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (BGB-16673-101) [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

4401

.

91.

Li

J

,

Xu

W

,

Yan

P

,

Cao

Y

,

Hu

M

,

Daley

W

.

Abstract CT128: phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies

.

Cancer Res

.

2023

;

83

(

8 suppl

):

CT128

.

92.

Accutar Biotech Pipeline

.

Latest progress of our drug discovery programs

. Accessed 13 September 2023. https://www.accutarbio.com/workflow/.

93.

AbbVie Pipeline

.

Advanced medicines that demonstrate both strong clinical performance and benefits to patients

. Accessed 1 November 2023. https://www.abbvie.com/science/pipeline.html.

94.

Shastri

A

,

Feldman

EJ

,

Starodub

AN

, et al.

Preliminary safety, pharmacokinetics, pharmacodynamics and clinical activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

3081

.

95.

Lue

JK

,

Stevens

DA

,

Williams

ME

, et al.

Phase 1 study of KT-413, a targeted protein degrader of IRAK4 and IMiD substrates, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

12143

-

12144

.

96.

He

Y

,

Koch

R

,

Budamagunta

V

, et al.

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

.

J Hematol Oncol

.

2020

;

13

(

1

):

95

.

97.

Foley

K

,

Dai

Y

,

Ding

Q

, et al.

Tumor-selective, chaperone-mediated protein degradation (CHAMP) of the bromodomain transcription factor BRD4 [abstract]

.

Eur J Cancer

.

2022

;

174

:

S27

.

98.

Burger

JA

,

Wiestner

A

.

Targeting B cell receptor signalling in cancer: preclinical and clinical advances

.

Nat Rev Cancer

.

2018

;

18

(

3

):

148

-

167

.

99.

Vetrie

D

.

The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

.

Nature

.

1993

;

364

(

6435

):

362

.

100.

Pal Singh

S

,

Dammeijer

F

,

Hendriks

RW

.

Role of Bruton’s tyrosine kinase in B cells and malignancies

.

Mol Cancer

.

2018

;

17

(

1

):

57

.

101.

Woyach

JA

,

Furman

RR

,

Liu

TM

, et al.

Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib

.

N Engl J Med

.

2014

;

370

(

24

):

2286

-

2294

.

102.

Wang

E

,

Mi

X

,

Thompson

MC

, et al.

Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors

.

N Engl J Med

.

2022

;

386

(

8

):

735

-

743

.

103.

Lampson

BL

,

Brown

JR

.

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?

.

Expert Rev Hematol

.

2018

;

11

(

3

):

185

-

194

.

104.

Aslan

B

,

Kismali

G

,

Iles

LR

, et al.

Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia

.

Blood Cancer J

.

2022

;

12

(

5

):

80

.

105.

Mato

AR

,

Shah

NN

,

Jurczak

W

, et al.

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

.

Lancet

.

2021

;

397

(

10277

):

892

-

901

.

106.

Naeem

A

,

Utro

F

,

Wang

Q

, et al.

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

.

Blood Adv

.

2023

;

7

(

9

):

1929

-

1943

.

107.

Blombery

P

,

Thompson

ER

,

Lew

TE

, et al.

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross resistance

.

Blood Adv

.

2022

;

6

(

20

):

5589

-

5592

.

108.

Noviski

MA

,

Ma

J

,

Lee

E

, et al.

Abstract 1126: concurrent degradation of BTK and IMiD neosubstrates by NX-2127 enhances multiple mechanisms of tumor killing

.

Cancer Res

.

2022

;

82

(

suppl 12

):

1126

.

109.

Montoya

S

,

Bourcier

J

,

Thompson

MC

, et al.

Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

1811

-

1813

.

110.

Mato

AR

,

Wierda

WG

,

Ai

WZ

, et al.

NX-2127-001, a first-in-human trial of NX-2127, a Bruton’s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

2329

-

2332

.

111.

Mato

A

,

Danilov

A

,

Patel

MR

, et al.

P649: a first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMID-like activity, in patients with relapsed and refractory B-cell malignancies [abstract]

.

Hemasphere

.

2022

;

6

:

547

-

548

.

112.

Robbins

DW

,

Noviski

M

,

Rountree

R

, et al.

Nx-5948, a selective degrader of BTK with activity in preclinical models of hematologic and brain malignancies [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

2251

.

113.

Feng

X

,

Wang

Y

,

Long

T

, et al.

P1239: Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less APT to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors (BTKI)

.

HemaSphere

.

2023

;

7

(

S3

):

e368855c

.

114.

Lee

T

,

Potts

SJ

,

Kantarjian

H

,

Cortes

J

,

Giles

F

,

Albitar

M

.

Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations

.

Cancer

.

2008

;

112

(

8

):

1744

-

1753

.

115.

Cortes

J

,

Lang

F

.

Third-line therapy for chronic myeloid leukemia: current status and future directions

.

J Hematol Oncol

.

2021

;

14

(

1

):

44

.

116.

Yang

Y

,

Gao

H

,

Sun

X

, et al.

Global PROTAC toolbox for degrading BCR–ABL overcomes drug-resistant mutants and adverse effects

.

J Med Chem

.

2020

;

63

(

15

):

8567

-

8583

.

117.

Ma

B

,

Feng

H

,

Feng

C

, et al.

Kill two birds with one stone: a multifunctional dual-targeting protein drug to overcome imatinib resistance in Philadelphia chromosome-positive leukemia

.

Adv Sci

.

2022

;

9

(

13

):

2104850

.

118.

Rouhimoghadam

M

,

Tang

H

,

Liao

J

, et al.

LPA81: discovery of an exceptionally potent Protac degrading native and mutant BCR-ABL1 oncoprotein in CML [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

485

-

486

.

119.

Hanahan

D

,

Weinberg

RA

.

Hallmarks of cancer: the next generation

.

Cell

.

2011

;

144

(

5

):

646

-

674

.

120.

Zaman

S

,

Wang

R

,

Gandhi

V

.

Targeting the apoptosis pathway in hematologic malignancies

.

Leuk Lymphoma

.

2014

;

55

(

9

):

1980

-

1992

.

121.

Bannerji

R

,

Kitada

S

,

Flinn

IW

, et al.

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance

.

J Clin Oncol

.

2003

;

21

(

8

):

1466

-

1471

.

122.

Tse

C

,

Shoemaker

AR

,

Adickes

J

, et al.

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

.

Cancer Res

.

2008

;

68

(

9

):

3421

-

3428

.

123.

Roberts

AW

,

Seymour

JF

,

Brown

JR

, et al.

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

.

J Clin Oncol

.

2012

;

30

(

5

):

488

-

496

.

124.

Wilson

WH

,

O’Connor

OA

,

Czuczman

MS

, et al.

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

.

Lancet Oncol

.

2010

;

11

(

12

):

1149

-

1159

.

125.

Schoenwaelder

SM

,

Jarman

KE

,

Gardiner

EE

, et al.

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

.

Blood

.

2011

;

118

(

6

):

1663

-

1674

.

126.

He

Y

,

Zhang

X

,

Chang

J

, et al.

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

.

Nat Commun

.

2020

;

11

(

1

):

1996

.

127.

Ottis

P

,

Palladino

C

,

Thienger

P

, et al.

Cellular resistance mechanisms to targeted protein degradation converge toward impairment of the engaged ubiquitin transfer pathway

.

ACS Chem Biol

.

2019

;

14

(

10

):

2215

-

2223

.

128.

Zhang

L

,

Riley-Gillis

B

,

Vijay

P

,

Shen

Y

.

Acquired resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) caused by genomic alterations in core components of E3 ligase complexes

.

Mol Cancer Ther

.

2019

;

18

(

7

):

1302

-

1311

.

129.

Shirasaki

R

,

Matthews

GM

,

Gandolfi

S

, et al.

Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins

.

Cell Rep

.

2021

;

34

(

1

):

108532

.

130.

Jiang

B

,

Gao

Y

,

Che

J

, et al.

Discovery and resistance mechanism of a selective CDK12 degrader

.

Nat Chem Biol

.

2021

;

17

(

6

):

675

-

683

.

131.

Kurimchak

AM

,

Herrera-Montávez

C

,

Montserrat-Sangrà

S

, et al.

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells

.

Sci Signal

.

2022

;

15

(

749

):

eabn2707

.

132.

Cotton

AD

,

Nguyen

DP

,

Gramespacher

JA

,

Seiple

IB

,

Wells

JA

.

Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1

.

J Am Chem Soc

.

2021

;

143

(

2

):

593

-

598

.

133.

Shih

P-C

,

Naganuma

M

,

Demizu

Y

,

Naito

M

.

Current status of oligonucleotide-based protein degraders

.

Pharmaceutics

.

2023

;

15

(

3

):

765

.

134.

Roberts

TC

,

Langer

R

,

Wood

MJA

.

Advances in oligonucleotide drug delivery

.

Nat Rev Drug Discov

.

2020

;

19

(

10

):

673

-

694

.

135.

Imaide

S

,

Riching

KM

,

Makukhin

N

, et al.

Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity

.

Nat Chem Biol

.

2021

;

17

(

11

):

1157

-

1167

.

136.

Lim

S

,

Khoo

R

,

Peh

KM

, et al.

bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA)

.

Proc. Natl. Acad. Sci

.

2020

;

117

(

11

):

5791

-

5800

.

137.

Hatakeyama

S

,

Watanabe

M

,

Fujii

Y

,

Nakayama

KI

.

Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation

.

Cancer Res

.

2005

;

65

(

17

):

7874

-

7879

.

138.

Pan

T

,

Zhang

Y

,

Zhou

N

, et al.

A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth

.

Oncotarget

.

2016

;

7

(

28

):

44299

-

44309

.

139.

Liu

C

,

Shi

Q

,

Huang

X

,

Koo

S

,

Kong

N

,

Tao

W

.

mRNA-based cancer therapeutics

.

Nat Rev Cancer

.

2023

;

23

(

8

):

526

-

543

.

https://doi.org/10.1101/2022.04.22.489232

140.

Yang

J

,

Sun

J

,

Zhu

J

, et al.

Circular mRNA encoded PROTAC (RiboPROTAC) as a new platform for the degradation of intracellular therapeutic targets

.

bioRxiv

.

Preprint posted online 22 April 2022

.

141.

Jin

Y-H

,

Lu

M-C

,

Wang

Y

, et al.

Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown

.

J Med Chem

.

2020

;

63

(

9

):

4644

-

4654

.

142.

Pfaff

P

,

Samarasinghe

KTG

,

Crews

CM

,

Carreira

EM

.

Reversible spatiotemporal control of induced protein degradation by bistable PhotoPROTACs

.

ACS Cent Sci

.

2019

;

5

(

10

):

1682

-

1690

.

143.

Xue

G

,

Wang

K

,

Zhou

D

,

Zhong

H

,

Pan

Z

.

Light-induced protein degradation with photocaged PROTACs

.

J Am Chem Soc

.

2019

;

141

(

46

):

18370

-

18374

.

144.

Zhang

Q

,

Kounde

CS

,

Mondal

M

, et al.

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)

.

Chem Commun

.

2022

;

58

(

78

):

10933

-

10936

.

145.

Yang

C

,

Yang

Y

,

Li

Y

,

Ni

Q

,

Li

J

.

Radiotherapy-triggered proteolysis targeting chimera prodrug activation in tumors

.

J Am Chem Soc

.

2023

;

145

(

1

):

385

-

391

.

146.

Liu

H

,

Ren

C

,

Sun

R

, et al.

Reactive oxygen species-responsive pre-PROTAC for tumor-specific protein degradation

.

Chem Commun

.

2022

;

58

(

72

):

10072

-

10075

.

147.

Shi

S

,

Du

Y

,

Zou

Y

, et al.

Rational design for nitroreductase (NTR)-responsive proteolysis targeting chimeras (PROTACs) selectively targeting tumor tissues

.

J Med Chem

.

2022

;

65

(

6

):

5057

-

5071

.

148.

Xue

Y

,

Bolinger

AA

,

Zhou

J

.

Novel approaches to targeted protein degradation technologies in drug discovery

.

Expert Opin Drug Dis

.

2023

;

18

(

4

):

467

-

483

.

149.

Dong

G

,

Ding

Y

,

He

S

,

Sheng

C

.

Molecular glues for targeted protein degradation: from serendipity to rational discovery

.

J Med Chem

.

2021

;

64

(

15

):

10606

-

10620

.

150.

Słabicki

M

,

Kozicka

Z

,

Petzold

G

, et al.

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

.

Nature

.

2020

;

585

(

7824

):

293

-

297

.

151.

Dikic

I

.

Proteasomal and autophagic degradation systems

.

Annu Rev Biochem

.

2017

;

86

(

1

):

193

-

224

.

152.

Paudel

RR

,

Lu

D

,

Roy Chowdhury

S

,

Monroy

EY

,

Wang

J

.

Targeted protein degradation via lysosomes

.

Biochemistry

.

2023

;

62

(

3

):

564

-

579

.

153.

Ding

Y

,

Xing

D

,

Fei

Y

,

Lu

B

.

Emerging degrader technologies engaging lysosomal pathways

.

Chem Soc Rev

.

2022

;

51

(

21

):

8832

-

8876

.